Unfortunately, patients with advanced BrCa are usually PR−/ER− and become eventually unresponsive to selective PR and ER modulators [131,132], requiring chemotherapy as second-line treatment with severe adverse effects [133,134]. The gene discussed is ESR1; the disease is invasive breast carcinoma.